Ben S. Wittner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ben S. Wittner has a total of 210 co-authors. Here are the top co-authors by number of shared publications:
- David T. Ting
Krantz Family Center for Cancer Research, Mass General Brigham Cancer Institute, Harvard Medical School, Boston, Massachusetts
32 shared publications Taronish D. Dubash
26 shared publicationsBenjamin Wesley
25 shared publications- Linda T. Nieman
Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
25 shared publications Mehmet Toner
22 shared publications- Genevieve Marie Boland
Massachusetts General Hospital (MGH) Department of Surgery, MGH Krantz Center for Cancer Research, Boston, USA
21 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Differential Kinase Activity Across Prostate Tumor Compartments Defines Sensitivity to Target Inhibition
Supplementary Figure from Differential Kinase Activity Across Prostate Tumor Compartments Defines Sensitivity to Target Inhibition
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Differential Kinase Activity Across Prostate Tumor Compartments Defines Sensitivity to Target Inhibition
Supplementary Figure from Differential Kinase Activity Across Prostate Tumor Compartments Defines Sensitivity to Target Inhibition
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Differential Kinase Activity Across Prostate Tumor Compartments Defines Sensitivity to Target Inhibition
Supplementary Data from Differential Kinase Activity Across Prostate Tumor Compartments Defines Sensitivity to Target Inhibition
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Differential Kinase Activity Across Prostate Tumor Compartments Defines Sensitivity to Target Inhibition
Supplementary Data from Differential Kinase Activity Across Prostate Tumor Compartments Defines Sensitivity to Target Inhibition
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Differential Kinase Activity Across Prostate Tumor Compartments Defines Sensitivity to Target Inhibition
Supplementary Data from Differential Kinase Activity Across Prostate Tumor Compartments Defines Sensitivity to Target Inhibition
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Differential Kinase Activity Across Prostate Tumor Compartments Defines Sensitivity to Target Inhibition
Supplementary Data from Differential Kinase Activity Across Prostate Tumor Compartments Defines Sensitivity to Target Inhibition
- Top Cited PapersOpen Access
- 2 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product
Circulating Tumor Cells (CTCs) in blood encompass DNA, RNA, and protein biomarkers, but clinical utility is limited by their rarity. To enable tumor epitope-agnostic interrogation of large blood volumes, we developed a high-throughput microfluidic device, depleting hematopoietic cells through high-flow channels and force-amplifying magnetic lenses. Here, we apply this technology to analyze patient-derived leukapheresis products, interrogating a mean blood volume of 5.83 liters from seven patients with metastatic cancer. High CTC yields (mean 10,057 CTCs per patient; range 100 to 58,125) reveal considerable intra-patient heterogeneity. CTC size varies within patients, with 67% overlapping in diameter with WBCs. Paired single-cell DNA and RNA sequencing identifies subclonal patterns of aneuploidy and distinct signaling pathways within CTCs. In prostate cancers, a subpopulation of small aneuploid cells lacking epithelial markers is enriched for neuroendocrine signatures. Pooling of CNV-confirmed CTCs enables whole exome sequencing with high mutant allele fractions. High-throughput CTC enrichment thus enables cell-based liquid biopsy for comprehensive monitoring of cancer.
- 2 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
Top Cited PapersOpen AccessTumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product
Circulating Tumor Cells (CTCs) in blood encompass DNA, RNA, and protein biomarkers, but clinical utility is limited by their rarity. To enable tumor epitope-agnostic interrogation of large blood volumes, we developed a high-throughput microfluidic device, depleting hematopoietic cells through high-flow channels and force-amplifying magnetic lenses. Here, we apply this technology to analyze patient-derived leukapheresis products, interrogating a mean blood volume of 5.83 liters from seven patients with metastatic cancer. High CTC yields (mean 10,057 CTCs per patient; range 100 to 58,125) reveal considerable intra-patient heterogeneity. CTC size varies within patients, with 67% overlapping in diameter with WBCs. Paired single-cell DNA and RNA sequencing identifies subclonal patterns of aneuploidy and distinct signaling pathways within CTCs. In prostate cancers, a subpopulation of small aneuploid cells lacking epithelial markers is enriched for neuroendocrine signatures. Pooling of CNV-confirmed CTCs enables whole exome sequencing with high mutant allele fractions. High-throughput CTC enrichment thus enables cell-based liquid biopsy for comprehensive monitoring of cancer.